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Glucose-induced augmented vascular endothelial growth factor (VEGF) 
production is a key event in diabetic retinopathy. We have previously 
demonstrated that downregulation of miR-200b increases VEGF, mediating 
structural and functional changes in the retina in diabetes. However, mechanisms 
regulating miR-200b in diabetes are not known. Histone methyltransferase 
complex, Polycomb Repressive Complex 2 (PRC2), has been shown to repress 
miRNAs in neoplastic process. We hypothesized that, in diabetes, PRC2 
represses miR-200b through its histone H3 lysine-27 trimethylation mark. We 
show that human retinal microvascular endothelial cells exposed to high levels of 
glucose regulate miR-200b repression through histone methylation, and that 
inhibition of PRC2 increases miR-200b while reducing VEGF. Furthermore, 
retinal tissue from animal models of diabetes, showed increased expression of 
major PRC2 components, demonstrating in vivo relevance. This research 
established a repressive relationship between PRC2 and miR-200b, providing 
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1.1 Diabetes Mellitus 
Diabetes mellitus is a metabolic disorder characterized by impaired 
glucose utilization. It is defined as an absolute or relative deficiency of insulin, 
leading to hyperglycemia (1). There are two major types of diabetes, which are 
distinct in both their etiology and treatment strategy. Type 1 diabetes is also 
known as juvenile-onset diabetes because patients typically present with glucose 
utilization problems in their youth (2). The etiology of type 1 diabetes is believed 
to result from auto-immune destruction of the beta-cells of the pancreas, which 
function normally to secrete insulin in response to elevations in blood glucose 
levels. As a result, these patients have an absolute lack of insulin. 
Supplementation of exogenous insulin is the major treatment strategy for these 
patients, and continual blood glucose monitoring and insulin administration with 
pumps have allowed these patients to live relatively normal lives. Conversely, 
patients with type 2 diabetes present at middle to late age, although this trend is 
changing as we see more type 2 diabetes in children and young adults. 
Etiologically, type 2 diabetes is believed to result from lifestyle habits, such as 
diets high in carbohydrates and lack of physical exercise. Obesity is well linked to 
insulin resistance. As a result, the pancreas must secrete insulin at a much more 
rapid rate than in healthy patients (2,3). Eventually the beta-cells become 
exhausted, resulting in impaired insulin secretion in combination with insulin 
resistance. Medications may be necessary to treat type 2 diabetes. For example 
metformin is commonly prescribed to type 2 patients and functions to improve 
	  3 
insulin sensitivity. In patients who have severe type 2 diabetes with very difficult 
to control blood glucose levels, insulin supplementation may be required.  
 While management of blood glucose levels has improved, regardless of 
whether a patient has type 1 or type 2 diabetes they remain susceptible in the 
long term to hyperglycemia-induced complications (4,5,6). These include diabetic 
retinopathy, cardiomyopathy, nephropathy and others. These complications can 
reduce the quality of the life of patients with diabetes and can even lead to early 
death. Investigating how hyperglycemia causes signaling changes at a cellular 
level can lead to new treatment strategies to prevent these complications. 
 
1.2 Epidemiology 
Incidence of diabetes is a growing phenomenon in recent years and 
affects both the developed and undeveloped world. The World Health 
Organization (WHO) estimates that more than 347 million people worldwide have 
diabetes (7). In the United States, the incidence of diabetes in individuals older 
than 18 years old has increased by three fold since 1980 (8). Indeed, diabetes is 
no longer a disease of the young (type 1) or of the elderly (type 2). The incidence 
of both type 1and type 2 diabetes has increased in the adolescent population and 
working age population, highlighting the growing problem of diabetes in society 
(9,10).  
In Canada, the growth of diabetes is more modest than in the United 
States but is significant none-the-less. Nearly 2.85 million Canadians are 
estimated to be currently living with diabetes, either diagnosed or undiagnosed. 
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Since 1999, the prevalence of diabetes in Canada has increased by 70% (8). 
Type 1 diabetes remains the most prevalent type of diabetes in youth, however 
type 2 incidence is growing. Canadians with diabetes are at 3 times greater risk 
for cardiovascular disease, 12 times greater risk for end-stage renal disease and 
20 times greater risk for limb amputation compared to healthy individuals. 
Overall, diabetics have two fold increased risk of mortality. Research into 
pathogenic signaling mechanisms involved in diabetes is necessary to develop 
new treatment strategies to maintain the quality of life of patients with diabetes, 
as well as to prevent diabetes-associated early death. 
 
1.3 Diabetic Retinopathy and Pathogenic Signaling 
Diabetic retinopathy is a microvascular complication of diabetes and a 
leading cause of vision loss (11). In early diabetic retinopathy, hyperglycemia 
induces the expression of vasoactive and inflammatory factors that increase 
retinal capillary permeability, causing macular edema, and contributing to 
pericyte and endothelial cell loss (4). Extracellular matrix (ECM) proteins also are 
increased, contributing to basement membrane thickening (12). As diabetic 
retinopathy progresses, microaneurysms develop and new vessels are formed. 
New vessels may lead to bleeding and tractional retinal detachment, leading to 
vision loss. Sustained hyperglycemia, elevated blood pressure and abnormal 
plasma lipids are all important risk factors in the progression of chronic diabetic 
complications including retinopathy. However large scale studies in both types of 
diabetes, such as the Diabetes Control and Complications Trial (DCCT), the 
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Epidemiology of Diabetes Interventions and Complications (EDIC) and the United 
Kingdom Prospective Diabetes Study (UKPDS), have shown that hyperglycemia 
is the main factor in the development of microvascular complications (13,14,15). 
Intensive glycemic control is important to delay the onset and progression of 
diabetic retinopathy, however this cannot always be achieved.  
 
1.3.1 Intracellular signaling events  
  There are numerous signaling events and pathways that are involved in 
altering the expression of vasoactive factors like vascular endothelial growth 
factor (VEGF). Chronic, poorly controlled glucose first leads to signaling changes 
in endothelial cells of the eye. Endothelial cells are particularly susceptible to 
hyperglycemcia-induced damage due to their constitutive expression of glucose 
transporter 1 (GLUT-1) (16,17,18). As a result, elevated glucose first causes 
signaling changes in these cells, which manifests in altered signals to other cell 
types in target organs.  
A number of mechanisms are involved in hyperglycemia-induced damage. 
Increased intracellular glucose increases protein glycosylation and leads to 
production of advanced glycation end products (AGEs), which disrupt protein 
signaling and trafficking (19). Furthermore, excessive intracellular glucose 
becomes shunted down other metabolic pathways, such as the Polyol pathway. 
This metabolic pathway reduces nicotinamide adenine dinucleotide phosphate 
(NADPH) levels and impairs the reducing capability of the cell, resulting in 
increased reactive oxygen species (ROS) (20,21). ROS is particularly damaging 
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in diabetes where defective antioxidant activity (ie. MnSOD) exacerbates 
damage to the retina.  ROS stimulate the generation of intracellular signals and 
activate pathways such as protein kinase C (PKC), c-Jun-N-terminal kinase 
(JNK), and p38 mitogen-activated protein kinase (MAPK). These pathways 
induce numerous functional changes; including endothelial dysfunction mediated 
through altered endothelial nitric oxide synthase (eNOS) activity and enhanced 
superoxide production (22,23).  
Signaling cascades from metabolic changes converge in the nucleus as 
activation of various transcription factors. For example, forkhead box O (FOXO) 
and nuclear factor κB (NF-κB), which can mediate the effects of ROS through 
regulation of gene transcription of inflammatory and antioxidant genes (24). 
Oxidative stress also causes DNA damage and together activates DNA repair 
enzymes, transcription factors, and transcription co-activators in endothelial cells. 
The activated nucleotide excision repair enzymes include excision repair cross 
complimenting 1 (ERCC1), ERCC4 (also known as Xeroderma Pigmentosum 
complementation group F) and poly(ADP-ribose) polymerase (PARP) (25). In 
parallel, there is augmented production of histone acetyl transferase p300 and 
alterations of histone deacetylases including the class III deacetylases, the 
sirtuins (26,27,28). Abnormal chromatin modifications, such as acetylation, 
methylation, phosphorylation, sumoylation, and ubiquitination, occur at specific 
residues in the N-terminal tails of histones and further modulate gene expression 
(29). Altogether, these changes in the nucleus alter the expression of various 
	  7 
genes associated with diabetic complications, which further mediate the organ’s 
response to hyperglycemic conditions. 
 
1.3.2 Transcriptional changes and extracellular consequences 
The functional consequence of the altered signaling events in diabetes is 
increased transcription of multiple vasoactive factors and ECM proteins, which 
are involved in the development and progression of chronic diabetic 
complications. Inflammatory and angiogenic cytokines elevated in diabetes signal 
to increase permeability and proliferation in the retina. These mediators include 
vascular endothelial growth factor (VEGF), endothelin (ET-1), interleukins (ILs) 
and other factors (30,31,32). Accumulation of ECM proteins, such as fibronectin 
(FN) or collagen, thickens the basement membrane and further contributes to 
vascular dysfunction and increased ocular permeability (12). As a result, vessel 
integrity is compromised and there is greater risk of microaneurysm and 
hemorrhage, which occur commonly in diabetic retinopathy. Over time the altered 
microenvironment induced by hyperglycemia changes and deteriorates the 
structure of the retina, leading to decreased function and vision loss.  
 
1.3.3 Current treatment strategies 
Maintaining tight glycemic control with medications and lifestyle changes 
has been the major therapeutic strategy and has been shown to prevent or slow 
down the development of diabetic retinopathy (33). However, some patients, still 
experience elevated glucose levels and thus remain susceptible to diabetic 
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retinopathy (4). Research into key pathogenic targets that mediate diabetic 
retinopathy has uncovered an important role of VEGF. VEGF is a growth factor 
that is elevated in the eye in diabetes, which has been shown at both mRNA and 
protein levels (34,35,36,37). VEGF causes increased vessel permeability in the 
early stages of diabetic retinopathy, and mediates endothelial cell migration and 
neovascularization in the late stages of diabetic retinopathy. Targeted therapy to 
inhibit VEGF has been a leading strategy for years in the treatment of diabetic 
retinopathy (38,39).  
Targeted inhibitory therapy against VEGF receptor using a monoclonal 
antibody has also been shown to be effective in preventing microaneurysm 
formation and improving visual acuity in patients with diabetic retinopathy 
(38,39,40,41). While VEGF-antibody has shown efficacy in both of these aspects, 
pharmacological therapy is not effective for all patients. For example, 40% of 
patients show no improvements in visual acuity following VEGF-antibody 
treatment (41). It is also invasive, as these patients must have eye injections 
monthly for one to three years. Furthermore, in Ontario the current cost of VEGF-
antibody treatment is over $1,500 per injection, which is not funded by the 
provincial drug plans (42). As a result, this treatment carries a high cost to both 
the health care system and the patient. With diabetes becoming an epidemic 
across the developed and underdeveloped world, research into additional 
therapies is needed to improve our understanding of the pathogenic mechanisms 
of diabetic retinopathy, as well as to deliver a more efficacious treatment to more 
people.  
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1.4 microRNAs  
Recent research has uncovered an underlying layer of microRNA (miRNA) 
involvement in most biologic processes and several diseases, such as cancer or 
diabetes. miRNAs, a group of noncoding RNAs, are well-studied epigenetic 
elements and have shown important interactions in many pathogenetic 
processes. miRNAs are post-transcriptional regulators of gene expression. They 
are produced initially by RNA Polymerase 2 (Pol2) as immature transcripts and 
are processed into shorter, mature miRNAs (43,44). Mature miRNAs target 
messenger RNAs (mRNAs) for inhibition through specific binding at the 3’ 
untranslated region (UTR), triggering mRNA degradation or halting translation 
depending on complementarity (45). Unlike miRNA, other noncoding RNAs have 
more complicated functions in chromosomal modifications, gene transcription 
and translation (46). miRNAs target many genes for inhibition, and databases 
have been developed to predict these interactions (47,48,49). Currently, more 
than 700 miRNAs have been identified in the human genome and it is estimated 
that approximately 30% of the human genome is regulated by miRNAs (50). 
From an evolutionary perspective, miRNAs represent another level of control 
over cellular events by tightly regulating gene expression (Figure 1.1A). 
Therefore, aberrant miRNA expression in disease processes can disrupt normal 
cell physiology and mediate pathogenetic processes (51,52). Altered miRNA 
expression generally has 2 possibilities: increased miRNA expression inhibits 
specific mRNA expression, whereas decreased miRNA expression enhances 
specific mRNA expression (Figure 1.1B). In diabetes, altered metabolic events  
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Figure 1.1 
Functions and implications of altered microRNA expression in disease states.  
(A) At the post-transcriptional level, miRNAs function to regulation gene 
expression by targeting mRNAs for degradation or inhibition. (B) Increased 
miRNA results in increased inhibition of target genes, often resulting in reduced 
protective factors. Decreased miRNA results in decreased inhibition of target 
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lead to alterations of gene transcription. Such changes may also lead to changes 
in miRNA expression as both are under similar regulation (51). 
miRNAs have been silently involved in the pathogenesis of many 
diseases. It is only in recent years that the importance of these background 
players is beginning to be understood in chronic diabetic complications. 
Understanding epigenetic elements, such as miRNA, can yield new therapeutic 
strategies. 
 
1.5 microRNAs in diabetic retinopathy 
1.5.1 miRNAs involved with vasoactive factors and matrix protein  
accumulation 
In diabetic retinopathy, several miRNA have been shown to be involved. 
Major investigations have been performed with miR-200b and miR-146a. In this 
section, several miRNAs related to diabetic retinopathy will be discussed, as well 
as the potential therapeutic efficacy of one promising miRNA, miR-200b. 
Increased retinal capillary permeability and other changes are mediated 
by increased production of specific factors, including VEGF. One miRNA, miR-
200b, has been shown to regulate VEGF (53). miR-200b is produced from cluster 
of human chromosome 1, along with related miRNAs miR-200a and miR-429. 
Our laboratory has shown decreased miR-200b in bovine retinal endothelial cells 
exposed to high levels of glucose, as well as in retinal tissue of streptozotocin-
induced (STZ) diabetic rats at 1 month following diabetes induction. Due to loss 
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of negative regulation, VEGF expression and retinal permeability were enhanced. 
Intravitreal injections of miR-200b were protective by reducing VEGF as well as 
vessel permeability (53). Furthermore, miR-200b levels were decreased in 
human retinal tissue from diabetic patients compared to non-diabetic patients, 
further supporting that loss of miR-200b occurs in diabetic retinopathy and that 
restoring miR-200b may be therapeutically useful (Figure 1.2). Interestingly, 
another study in a genetic model of type 1 diabetes (BL/65-Ins2 Akita) found 
increased miR-200b expression relative to B6 control mice (54). In this model, 
increased miR-200b inhibited oxidation resistance 1 (Oxr1), a protective gene 
involved in resistance to oxidative stress. These studies differed in diabetic 
models (STZ vs. Akita), time points (1 month vs. 8 months), cell types cultured 
and studied (endothelial vs. Mueller cells) and as well as in vitro treatment 
conditions, which may have accounted for the differences in miR-200b 
expression relative to the non-diabetic controls. Nevertheless, it is possible that 
altered expression of miR-200b in either direction could have consequences. 
Matrix protein accumulation is another important feature contributing to 
structural abnormalities and eventual neovascularization (12). miR-146a 
regulates FN levels and is downregulated in the retina of the STZ rat model at 1 
month of diabetes (55). Furthermore, intra-ocular injection of miR-146a mimic 
reduced FN accumulation. miR-320 is downregulated in diabetic retinopathy and 
regulates extracellular signal related kinases 1 and 2 (ERK1/2; part of MAPK 
pathway) and activation of VEGF, ET-1 as well as FN. Restoring miR-320 may 
be protective in diabetic retinopathy by targeting ERK1/2 signalling (56).  
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Figure 1.2  
Relationship between diabetes, microRNA-200b (miR-200b) and vascular 
endothelial growth factor (VEGF). Previous work in our laboratory has 
demonstrated that miR-200b is downregulated in diabetes, leading to increased 
VEGF expression and increased permeability (44). Intraocular injection of miR-
200b mimic was found to be effective in reducing VEGF expression and vascular 
permeability, demonstrating miR-200b as a potential therapeutic agent. The 
understanding into why miR-200b becomes repressed is limited and is the focus 
of the current study. 	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Likewise, miR-126 is protective by inhibiting vasoactive factor expression, and 
loss of miR-126 resulted in increased VEGF levels, insulin-like growth factor 
(IGF)-2 and hypoxia- inducible factor-1 alpha (HIF-1α) (57). These factors play a 
major role in late- stage proliferative diabetic retinopathy by further mediating 
permeability changes and ECM protein accumulation, which eventually contribute 
to neovascularization and vision loss (4). 
 
1.5.2 Therapeutic potential 
Overall, miRNAs are important mediators of vascular permeability, matrix 
protein accumulation and neovascularization, which together can contribute to 
vision loss over time in diabetic patients. Of all the miRNAs described, miR-200b 
may have the greatest therapeutic potential for its regulation on VEGF. 
Administration of exogenous miR-200b may be efficacious in the treatment of the 
microvascular events of diabetic retinopathy, however there are several 
limitations. Most obviously, miRNAs are endogenous small interfering RNAs 
(siRNAs), and the current use of siRNAs as a therapy is limited only to 
experimental purposes (58). While siRNAs and miRNAs offer compelling 
therapeutic targets, little is understood about their safety, and the multitude of 
potential interactions could be a double-edged sword in disease management 
(59). Furthermore, although endogenous delivery mechanisms are being 
investigated, miRNAs have short half-lives in circulation and thus would have to 
be injected directly into the eye to treat a disease such as diabetic retinopathy, 
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offering no logistical advantage to current therapies (60). Instead, identifying a 
large molecule (ie. protein) which regulates these miRNAs may be a more 
attractive therapeutic strategy.  
Understanding into why miRNAs, like miR-200b, become dysregulated in 
diabetes is important to further our understanding of the disease, as well as 
identify molecular targets that may be important from a therapeutic perspective. 
Additional research in this topic is necessary, and current research suggests an 
epigenetic link between microRNA regulation and histone methylation.  
 
1.6  An epigenetic connection: histone methylation 
Histone modification is another emerging theme in the field of epigenetics 
and is involved in the coordination of gene expression. Amino acid residues 
within histone subunit molecules become modified in a variety of ways (ie. 
acetylation, methylation, phosphorylation etc.), by chromatin modifying enzymes, 
which changes the overall accessibility of chromatin and affects how transcription 
factors can activate/repress genes in the modified area (61). For example, 
acetylation can be thought of as an “activating mark,” as areas of the genome in 
which histones are highly acetylated show high gene expression (62,63). The 
addition of an acetyl group is thought to make the chromatin more positively 
charged and thus more accessible for transcriptional machinery. Methylation is 
another histone modification process involved in gene expression but is more 
complicated and not as well understood as acetylation (64).  
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There are several key principles to keep in mind when discussing histone 
methylation. First, the amino acid which is methylated is important. Depending on 
the amino acid residue, the result can be activation or repression of gene 
expression in that area of the genome (65,66). For example, tri-methylation at 
lysine 4 on histone subunit 3 (H3K4me3) is typically activating, leading to 
recruitment of transcription factors and increased expression of genes. 
Conversely, tri-methylation at lysine 27 on histone subunit 3 (H3K27me3) is 
typically repressing, leading to closed chromatin.  
Second, existing methyl-marks can be recognized. Chromatin-modifying 
enzymes are able to recognize existing marks on histones with high specificity 
(67). For example, the recruitment of Polycomb Repressive Complex 2 (PRC2), a 
repressing histone methyltransferase complex, to a region of the genome is 
inhibited by existing H3K4, H3K36 methylation, H3K27 acetylation or H3K28 
phosphorylation (68). Past histone modification can therefore affect future 
genomic interaction between other modifying enzymes.  
Third, methyl-marks can be removed. Histone methylation is a reversible 
and dynamic process and there are many histone demethylases for each type of 
methylation (69). For example, Lysine-specific Demethylase 6A (KDM6A) and 6B 
(KDM6B) catalyze the demethylation of H3K27me3 and thus oppose or balance 
the activity of PRC2 (70). This reversibility of histone methylation adds to the 
complexity of interactions but allows for a more attractive therapeutic strategy.  
Finally, methyltransferases often complex with adaptor proteins or long 
non-coding RNA (lncRNA). Methyltransferases achieve specificity to regions of 
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the genome by associating with adaptor proteins and lncRNA. For example, 
Supressor of Zeste 12 (SUZ12) and Embryo Ectoderm Development (EED) are 
adaptor proteins that interact with Enhancer of the Zeste Homolog 2 (EZH2) to 
form PRC2, the major methyltransferase complex for H3K27 methylation. EED 
and SUZ12 allow for PRC2 recruitment to specific parts of the genome, which 
can be direct through complex protein structures or indirect through lncRNA 
(68,71). LncRNA are able to guide chromatin-modifying enzymes to specific 
genes through their polar structure; in which one end integrates within the gene 
and the free end recruits the enzyme (46). Similarly, lncRNA can act as 
molecular scaffolds to increase interactions between transcription factors and 
other chromatin modification enzymes.  
Research into the expression and activity of histone methyltransferases is 
booming in the cancer field and is becoming attractive in the diabetes field due 
the recently described phenomena of “metabolic memory.” Changes in gene 
expression and resultant vessel functionality due to hyperglycemia have been 
observed to persist long after returning to a normoglycemic state (72). So far only 
H3K4 and H3K9 methylation have been examined in cell culture studies and 
animal models of diabetes. However, evidence suggests that methylation is 






1.7 Polycomb Repressive Complex 2 
One particular type of methylation, H3K27me3, has been linked to miRNA 
regulation in several investigations. PRC2 is a repressing histone 
methyltransferase complex that has been linked to negatively regulating many 
genes, including miRNAs. In this section, the structure and function of PRC2 will 
be discussed, as well as potential regulatory relationships that may be of interest 
in diabetic retinopathy.  
 
1.7.1 Structure and Function of PRC2 
PRC2 is a multimeric complex that catalyzes trimethylation of lysine 27 on 
histone H3 (H3K27me3). This is a repressing type of methylation which leads to 
closed and inaccessible chromatin (77,78). Thus, PRC2 is believed to be a 
negative regulator of gene expression. The complex is composed of a 
methyltransferase portion, adaptor proteins, as well as lncRNA, which function in 
unison to regulate gene expression. Arguably the most important subunit is 
EZH2, which catalyzes the H3K27 trimethylation reaction (78). EZH2 has been 
extensively studied in human cancers and is responsible for alterations in tumour 
vasculature and invasiveness (79,80). Two other subunits of particular 
importance are EED and SUZ12. Unlike EZH2, EED and SUZ12 do not have 
direct methyltransferase catalytic function but instead are responsible for 
recruitment of EZH2 to different promoter regions (81,82). Specificity to different 
regions of the genome is mediated by direct protein-DNA interactions, as well as 
by recruitment through lncRNA, such as ANRIL or HOTAIR (83). These lncRNA 
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function as molecular flags to direct PRC2 to specific genome areas. They may 
also act as scaffolds to bring together chromatin remodeling complexes. Thus, 
the methyltransferase function of PRC2 is mediated by EZH2 while its specificity 
is mediated by EED and SUZ12, as well as lncRNA.  
Most of the functional importance of PRC2 has come from research in the 
cancer field. In a variety of cancers, PRC2 components such as EZH2 and 
SUZ12 are over expressed, leading to increased H3K27me3 at a variety of gene 
promoters. The functional result is silencing of expression in that area, resulting 
in increased angiogenesis and enhanced metastasis (84). Furthermore, 
increased expression of this complex has been shown be induced by VEGF. 
PRC2 is known to negatively regulate vasoinhibin-1 (VASH1), an anti-angiogenic 
factor, and can thus further enhance the angiogenic action of VEGF (79,85). 
Finally, PRC2 has been implicated in regulating cell-cell adhesion and 
inflammatory genes in endothelial cells (86).  
  
1.7.2 PRC2 and microRNA regulation 
PRC2, and specifically the EZH2 and SUZ12 subunits, have been shown 
to regulate several microRNA in the context of neoplasia. Interestingly, there is 
an overlap of several microRNAs, which are repressed both in diabetic 
complications and cancer (87). For example, miR-200b is important in the 
context of diabetic retinopathy for its regulation on VEGF, which mediates 
increased permeability in the eye and eventual neovascularization as the disease 
progresses (53). miR-200b is also implicated in several cancers (88). In cancer, 
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miR-200b is known as tumour suppressor gene that becomes downregulated or 
mutated in cancer (88). This loss of inhibition leads to increased expression of 
target genes, which mediates increased tumour invasiveness. In human 
fibroblasts, increased H3K27me3 was found at the promoter regions of the miR-
200 gene cluster with correlating decreased expression relative to epithelial cells, 
illustrating a mechanism for how miR-200b becomes repressed (89).  
 
1.8 Rationale 
While there is limited understanding as to why microRNAs like miR-200b 
become repressed in diabetic complications, based on the above discussion, it is 
possible that the underlying regulation of miR-200b may involve PRC2 (Figure 
1.3). Altogether, the importance of miR-200b in diabetic retinopathy, with 
possible links of PRC2 to miR-200b, provides clear rationale for investigating this 
complex in the context of diabetic retinopathy. Involvement of PRC2 in diabetic 
retinopathy remains elusive, as well as links to VEGF and angiogenesis, 
providing additional motivation for the current study. 
 
1.9 Hypothesis 
We hypothesize that glucose induces increased PRC2 expression and 
activity, which causes alteration of miR-200b levels. Such changes may play a 











Figure 1.3  
Schematic showing our working hypothesis. (A) Glucose-induced increased 
PRC2 expression and activity causes alteration of miR-200b levels. Such 
changes may play a role in the development of diabetic retinopathy. (B) This 
relationship is hypothesized to be regulated at the level of genome by PRC2-
















 	  	  











1.10 Specific Aims 
To test our hypothesis, we have devised 4 objectives: 
1. To investigate the effect of glucose on VEGF levels in human retinal 
microvascular endothelial cells. 
2. To investigate the effect of glucose on PRC2 levels and activity in human 
retinal microvascular endothelial cells. 
3. To investigate whether PRC2 components are altered in retinal tissues of 
diabetic animals. 
4. To investigate the regulatory relationship between PRC2 and miR-200b. 



























2.1 In Vitro Studies 
2.1.1 Human Retinal Microvascular Endothelial Cells 
To investigate PRC2 and miR-200b regulation in the context of diabetic 
retinopathy, the major cell type used for investigation was the human retinal 
microvascular endothelial cell (HRMECs, Olaf Pharmaceuticals, Worchester, 
MA).  
HRMECs were grown and passaged in tissue culture flasks in Endothelial 
Basal Medium 2 (EBM-2; Lonza, Walkersville, MD) containing 5mM D-glucose, 
10% fetal bovine serum (FBS; Sigma-Aldrich, Oakville, ON) and all provided 
growth factors and antibiotics (EBM-2 Single Quots). No additional antibiotic was 
added to the medium. HRMECs were incubated at 37°C with 5% CO2 and used 
between passages 3 and 8 to minimize variability. Prior to experimentation, 
HRMECs were seeded on the appropriate dish based on the assay. At 80-90% 
confluency, HRMECs were serum starved overnight by removing the growth 
medium and replacing it with EBM-2 containing 0% FBS, no growth factors or 
antibiotics. Serum starvation is important to remove the confounding variables 
(growth factors) in serum. Following starvation, cells were treated with additional 
D-glucose (Sigma-Aldrich, Oakville, ON) to represent high glucose levels (HG, 
25mM) with normal glucose controls (NG, 5mM). Osmotic controls were also 
used where necessary (20mM L-glucose + 5mM D-glucose). All experiments 




2.1.2 Human Dermal Microvascular Endothelial Cells 
 While HRMECs are the focus of most of the work in this study, other 
endothelial cell types were investigated to elucidate whether genes associated 
with PRC2 might be specific to retinal endothelial cells. Furthermore, human 
dermal microvascular endothelial cells (HDMECs) have been used to model 
diabetic vascular complications by our laboratory and others.  
HDMECs isolated from non-diabetic individuals (Lonza) and type 1 and 
type 2 diabetic individuals (Lonza) were cultured identically to HRMECs. 
HDMECs from non-diabetic individuals were isolated from adult foreskin and 
were pooled together from multiple donors. HDMECs of type 1 diabetes origin 
(type 1) were isolated from a 62-year-old female type 1 diabetic patient with a 
body-mass index (BMI) of 22. HDMECs of type 2 diabetes origin (type 2) were 
isolated from a 73-year-old female type 2 diabetic patient with a BMI or 29.  
 
2.2 In Vivo Studies  
 Male Sprague–Dawley rats (175 g, 6 weeks old) were obtained (Charles 
River, Wilmington, MA, USA). Diabetes was induced by a single intraperitoneal 
injection of streptozotocin (STZ, 65mg/kg, in citrate buffer 5.6pH), with control 
rats receiving an identical volume of citrate buffer. Rats were monitored for 
changes in body weight and blood glucose. After 4 weeks of diabetes duration, 
rats were sacrificed, retinal tissue was collected and RNA was extracted as 
described below. All animal experimentation was carried out in accordance to 
Western University and Animal Care and Veterinary Services Guidelines.  
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 Male C57BL/6 mice (23-36gm, were administered three doses STZ 
(50mg/kg) to induce diabetes, with control animals receiving an identical volume 
of citrate buffer. Animals were monitored for changes in body weight and blood 
glucose. After 8 weeks of diabetes duration, mice were sacrificed and retinal 
tissue was collected.  
 
2.3 RNA Extraction and Real Time RT-PCR 
mRNA was extracted using techniques already established in our lab. 
Briefly, cells were collected in of TRIZOLTM reagent (Invitrogen, Burlington, ON). 
0.2mL of chloroform was added to the tube containing TRIZOLTM, vortexed 
vigorously. The samples were centrifuged at 15,000 × g for 15 minutes at 4°C 
and the aqueous layer was carefully recovered in a fresh tube. An equal volume 
of isopropanol was added to the aqueous layer. The mixture was vortexed briefly, 
and centrifuged at 15,000 × g for 15 minutes at 4°C. The pellet was washed with 
75% ethanol, dried, resuspended in DEPC water and quantified with 
spectrophotometry (260nm; Gene Quant, Pharmacia Biotech, USA).  
To generate cDNA, 2µg of total RNA was used with the High Capacity 
Reverse Transcription Kit (Applied Biosystems, Foster City, CA) and random 
hexamer primers. Quantitative Real time RT-PCR was performed using a Roche 
LightCycler 96 (Roche, Laval, QC) and SYBR Green detection (Clontech, 
Mountain View, CA). The reaction mixture (total volume 20µL) consisted of the 
following components: 10µL of SYBR Advantage qPCR Premix, 1µL of each 
10µM forward and reverse primer, 1µL cDNA sample and 7µL nuclease free 
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water. Primers for VEGF, EZH2, EED, SUZ12, KDM6A, and KDM6B are shown 
in Table 2.1 (Qiagen, Germantown, MD and Sigma-Aldrich). Normalization was 
performed to β-actin to account for differences in reverse transcription 
efficiencies of cDNA.  
 
2.4 miRNA Extraction and Real Time RT-PCR 
 To isolate miRNA, mirVana microRNA Isolation Kit  (Ambion, Austin, TX) 
was used. Cells were collected using and centrifuged at 200 × g for 4 minutes. 
The cell pellet was washed, transferred to a centrifuge tube and spun at 2600 × g 
rpm for 4 minutes. The pellet was resuspended in 500µL of lysis buffer. 50µL of 
miRNA Homogenate Additive was added to the lysate and the samples were left 
on ice for 10 minutes. Five hundred µL of Acid-Phenol:Chloroform (1:1) was 
added to the lysate and the mixture was vortexed. The mixture was centrifuged 
at 15,000 × g for 10 minutes at 4°C to separate the organic and aqueous layers. 
The aqueous layer was carefully removed and transferred to a fresh tube. Six 
hundred twenty five µL of 100% ethanol was added to the aqueous layer and the 
mixture was vortexed briefly. The mixture was filtered through a filter column in 
600µL batches, each time discarding the filtered solution following centrifugation. 
Sixty µL of preheated (95°C) Elution Solution was added to the filter column and 
the filter was centrifuged for 1 minute in a fresh tube. The RNA concentration 
was quantified using spectrophotometry (260nm). 
To generate cDNA, 100ng of total RNA was used with Reverse 
transcription was performed using the High Capacity Reverse Transcription Kit.  
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Table 2.1 Oligonucleotide sequences RT-PCR 
Genes Primer Sequences (5′ à  3′) 
  
β-actin (human/rat/mouse) CCTCTATGCCAACACAGTGC 
CATCGTACTCCTGCTTGCTG 
VEGF (human) GAACTTTCTGCTGTCTTGGG 
CTTCGTGATGATTCTGCCCT 
EZH2 (human) QIAGEN (QT00054614) 
EED (human) QIAGEN (QT00074627) 
SUZ12 (human) TACGGCTCCTATTGCCAAAC 
TGCTTCAGTTTGTTGCCTTG 
KDM6A (human) QIAGEN (QT00094654) 
KDM6B (human) QIAGEN (QT00098742) 
VASH1 (human) GTTCCCTCCGAAACTGAGAC 
ACAAAGCACCCCCATCTAAC 
EZH2 (rat) GCACACTGCAGAAAGATCCA 
AGGTAGCACGGACACTGCTT 
EZH2 (mouse) AGACGTCCAGCTCCTCTGAA 
CATCCTCAGTGGGAACAGGT 
EED (rat/mouse) CTGGCAAAATGGAGGATGAT 
GGTCAGTGTTGTGCATTTGG 













Specific primers are necessary to analyze mature miRNAs due to their short size. 
The RT-primer extends the template to create a suitable amplicon length for PCR 
analysis. TaqMan miRNA Assays (Applied Biosystems) were used as primers for 
Real Time RT-PCR (Table 2.2). miR-200b expression was quantified using this 
method and normalization was performed to house keeping gene U6.   
 
2.5 Chromatin Immunoprecipitation (ChIP) qPCR Analysis 
To elucidate changes in chromatin modifications associated with high 
glucose, ChIP-qPCR was performed. This technique allows pull down of specific 
protein targets and confirms genome association by performing qPCR with 
primers against select genomic regions. Chromatin Immunoprecipitation (ChIP) 
Assay Kit (Milipore, Temecula, CA) was used according to manufacturer’s 
instructions. Following 24 hours of glucose exposure, the cells were fixed using 
formalin. The plates were incubated at 37°C for 10 minutes and were 
immediately removed and washed twice with D-PBS. Five mL of D-PBS 
containing protease inhibitors was added to the plate and cells were carefully 
suspended using a cell lifter. The D-PBS mixture was transferred to a 15mL tube. 
An additional 5mL of D-PBS containing protease inhibitors was added to the 
plate to remove any remaining cells. The cells were centrifuged at 200 × g for 4 
minutes, and the pellet was washed once with D-PBS, transferred to a 1.7mL 
tube and recentrifuged to produce a pellet. The pellet was resuspended in 200µL 
of SDS lysis buffer containing protease inhibitors (Roche) and incubated on ice 
for 30 minutes, with brief vortexing at 10 minute intervals. The lysate was  
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Table 2.2 RT-PCR TaqMan miRNA Probe Sequences  
Genes 
 





























sonicated on ice three times in 30 second intervals with a KONTES Micro-
Ultrasonic Cell Disruptor (power of 6 at a tuning of 4) to attain DNA fragments in 
the 200-1000bp range, appropriate for immunoprecipitation. The lysate was 
centrifuged at 18,000 × g for 10 minutes to remove any insoluble cellular 
components and the supernanent was transferred to a fresh tube. The 
supernatent was precleared using Salmon Slurry Agarose for 30 minutes at 4°C 
with rotation. The mixture was briefly centrifuged for 1 minute at 100 × g and was 
transferred to a fresh tube. Eighty µL (5%) of each sample was transferred to a 
fresh tube and stored at -80°C for an input measurement. For each 
immunoprecipitation reaction, 1.6mL of each sample was used and extra sample 
discarded. Four µL of antibody (1:400 dilution) was used for each 
immunoprecipiation reaction. Antibody-chromatin mixture was incubated 
overnight at 4°C with rotation. 
Following 14 hours of rotation, 60µL of Salmon Slurry Agarose was added 
to each sample and the mixture was incubated for 1 hour at 4°C with rotation. 
The mixture was then centrifuged at 100 × g for 2 minutes and the agarose pellet 
was washed and re-centrifuged three times at 4°C (1. Low Salt Solution, 2. High 
Salt Solution, 3. Li-Cl Solution) and twice at room temperature (both 8.0 pH 
EDTA). Each wash was performed for 5 minutes with rotation. Following the final 
wash and centrifuge, precipitated DNA was released using 250µL of freshly 
prepared elution solution (1% SDS, 1M NaHCO3) rotating for 15 minutes at room 
temperature. This elution was repeated to assure effectiveness, for a 500uL 
eluate final volume. Twenty µL of 5M NaCl solution was added to the eluate and 
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the samples were incubated at 65°C for 4 hours to reverse cross-links. Following 
this incubation, 31.5µL of protease K inhibitor solution (Sigma-Aldrich) was 
added and incubated for 1 hour at 45°C to degrade proteins. Following this 
incubation, 500µL of phenol:cholorform (1:1) was added to each sample. The 
samples were vortexed vigorously for 30 seconds and centrifuged at 16,000 × g 
for 10 minutes at room temperature. The aqueous layer was carefully removed, 
transferred to a new tube, and 1.0mL of 100% ethanol and 150µL of 3M sodium 
acetate was added to each sample to induce DNA precipitation. The samples 
were mixed by inversion and were left in -20°C.  
After 12 hours, DNA was precipitated by centrifuging at 16,000 × g for 10 
minutes at 4°C. The supernatant was carefully removed. The pellet was washed 
once with 70% ethanol, re-centrifuged and dried. The pellet was resuspended in 
8.0 pH EDTA for use in subsequent qPCR analysis. 
Pulldown antibodies include anti-H3K27me3 and anti-Pol2 (Milipore). 
Control for these antibodies include IgG and ascitic fluid negative control. Primer 
design to the miR-200b promoter region was performed based on an identified 
promoter region 2kb upstream of the miR-200b gene (Sigma-Aldrich). Control 
primers provided by the manufacturer were used to assure the quality of the 
ChIP reaction, as well as to determine specificity of the chromatin modification 
changes associated with high glucose. Sequences for these primers are listed in 




Table 2.3 Oligonucleotides for ChIP-qPCR Analysis 
Genomic region 
 
Primer Sequences (5′ à  3′) 
 
miR-200b promoter GCCGGGATCACATTCCTC 
CTCAGCTTGGGAAAATCCAG 
Human alpha satellite CTGCACTACCTGAAGAGGAC 
GATGGTTCAACACTCTTACA 






















2.6 PRC2 inhibition with 3-Deazaneplanocin A (DZNep) chemical inhibitor 
A general methylation inhibitor DZNep (Cayman Chemical, Ann Arbor, 
MI), which has shown selectivity for PRC2 and H3K27me3, was used as a loss-
of-function treatment (80). DZNep is an indirect inhibitor of methylation, which 
functions by directly inhibiting a hydrolase that metabolizes Ado-Hcy. Ado-Hcy is 
a end product formed after a methyltransferase, like EZH2, uses its substrate, 
Ado-Met, to methylate an amino acid or nucleotide residue (50). DZNep therefore 
results in increased cellular levels of Ado-Hcy, which inhibits EZH2 by moving it 
to an inactive conformation. Concentrations from 1µM to 10µM have been shown 
to inhibit H3K27me3 activity and 5µM was used for these experiments (90).  
DZNep was initially dissolved in DMSO at a concentration of 10mM and 
was aliquoted for future use. DZNep was tested in normal glucose and high 
glucose, with an equal amount of DMSO (Santa Cruz Biotechnology, Santa Cruz, 
CA) as a control in the same conditions. Cells were pre-treated with DZNep at 
the starvation period, prior to addition of D-glucose, as well as during the D-
glucose treatments.  
 
2.7 PRC2 gene knockdown with small interfering RNA  
 To improve the specificity of the hypothesized mechanism, knockdown of 
specific gene targets was performed using small interfering (siRNA). Specifically, 
EZH2 and SUZ12 siRNA  (Qiagen) were used for gene knockdown with control 
siRNA to control for the transfection process and specificity (Table 2.4).  
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Table 2.4 Silencing small interfering RNA sequences 
Gene siRNA sequences (5′ à  3′) 

























Based on previous experiments in our laboratory, Lipofectamine was used 
in the following ratio based on past experiments in our laboratory (2.5µL 
Lipofectamine:1µg siRNA) with a final concentration of 100nM. To prepare this, 
siRNA and Lipofectamine 2000 (Invitrogen) was first mixed individually in Opti-
MEM (Life Technologies) containing reduced serum and no antibiotics. After five 
minutes, the individual solutions were combined, mixed by inversion, allowed to 
settle for 30 minutes. Cells were grown to 80% confluency and were washed with 
D-PBS prior to transfection to remove antibiotics. One mL of Opti-MEM 
containing siRNA was added to cells. The cells were transfected for 4 hours and 
was supplemented with 2x the volume of full EBM-2 containing 10% FBS, growth 
factors and antibiotics. 24 hours later, the full medium was replaced with serum-
free EBM-2 containing no growth factors or antibiotics and the cells were starved 
overnight. 18 hours later, cells were treated with D-glucose and were incubated 
for 48 hours, when they were collected for gene expression analysis as 
described above. Knockdown efficiency was measured by RT-PCR.  
 
2.8 Tube Formation Assay 
 As a measure of VEGF activity and angiogenesis, a tube formation assay 
was performed with transfected cells. BD Matrigel Matrix Phenol Red-Free (BD 
Biosciences, Bedford, MA) was aliquoted (100µL per well) into a 96-well plate. 
The plate was spun briefly to remove bubbles and was incubated for 1 hour at 
37°C. Prior to seeding, the transfected cells were collected with trypsin and 
cellular density was quantified using a hemocytometer.  Once the Matrigel 
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solidified, cells were seeded at a density of 1.5x104 cells per well. Density of cells 
plated was determined empirically. The cells were then incubated for 1 hour at 
37°C to allow for attachment, after which medium was aspirated and replaced 
with serum-free medium containing 25mM (HG) D-glucose.  Cells transfected 
with control siRNA were also cultured in 5mM (NG) D-glucose as a control. The 
plate was then returned to 37°C to allow for tube formation. After 16 hours, the 
medium was carefully aspirated from each well, the cells were washed once with 
D-PBS and pictures were taken at 40× magnification using a Nikon Diaphot 
microscope (Nikon Canada, Mississauga, ON) with PixeLINK camera and 
PixeLINK Capture OEM software (PixeLINK, Ottawa, ON). Branch numbers and 
branch points were counted and a ratio of branches:branch points was calculated 
for each treatment. Each treatment was repeated in triplicate with at least two 
field of views per replicate.  
 
2.9 Cell Viability Assay 
 To determine the cytotoxicity of the treatments used in our experiments, 
the WST-1 Cell Viability Assay (Roche) was used. Cells were seeded 
(5.0x104/well) onto a 96-well plate and were allowed to attach overnight. The 
following morning, the full medium was removed and was replaced with 100µL of 
serum-free medium containing various concentrations of D-glucose (5mM, 
10mM, 15mM, 25mM, 50mM, 100mM) and various concentrations of DZNep 
(50nM, 500nM, 5µM, 50µM, 500µM) with DMSO as a control 
(0.0005%,0.005%,0.05%,0.5%,5% v/v). Following 24 hours of incubation with the 
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agent, 10µL of WST-1 reagent was added to each well. The plate incubated for 
1.5 hours at 37°C to produce a colour reaction. Absorbance was measured with 
a Multiskan FC Microplate Photometer (Thermo Scientific, Finland) at 450nm 
with a reference wavelength of 690nm. Survival was determined by the 
difference between the absorbances at 450nm and 690nm.  
 
2.10 Statistical analysis 
 To determine statistical significance, 2-tailed Student’s T-test was 
performed with an α-value of 0.05 using SPSS. P values < 0.05 were considered 
stastically significant (*). For experiments with multiple groups, one-way ANOVA 
was performed with an α-value of 0.05 using SPSS. Tukey’s test was performed 
to determine differences between groups, with bars represented by different 
letters represented a significant difference, while a common letter denotes 
































3.1 High levels of glucose increase VEGF expression in HRMECs 
Based on previous experiments performed in our laboratory with different 
endothelial cell types, specific concentrations and time points for glucose 
exposure were selected for in vitro analysis. However, since the human retinal 
microvascular endothelial cell (HRMEC) type is a relatively a new model in our 
laboratory, experiments were performed to confirm whether glucose increase 
VEGF levels. We show that VEGF mRNA levels was significantly increased after 
24 hour exposure to medium containing 25mM glucose compared to 5mM 
glucose, while concentrations greater than 25mM did not show any differences in 
VEGF expression levels (Figure 3.1). The 25mM D-glucose exposure also 
showed decreased cell viability compared to 5mM D-glucose (Figure 3.2). 
Therefore, 5mM glucose was selected as normal glucose (NG) and 25mM 
glucose was selected as the high glucose (HG) for all subsequent analyses. 
These findings are consistent with previous studies performed in our laboratory 
using various endothelial cell types.  
To test the effects of glucose at different time points, HRMECs were 
exposed to 5mM or 25mM D-glucose for various durations. VEGF transcript 
levels were significantly increased in HG compared to NG at 24 hour and 48 
hours time points, though no significant changes were observed before these 
time points (Figure 3.3). Therefore, subsequent experiments were performed at 










Figure 3.1  
Real time RT-PCR analysis of VEGF mRNA at different concentrations of 
glucose. HRMECs exposed to various concentrations of D-glucose for 24 hours 
exhibited differential mRNA levels of VEGF. Compared to 5mM D-glucose, VEGF 
expression was significantly increased at 15mM and 25mM D-glucose 
concentrations. VEGF was not increased at concentrations higher than 25mM. [* 
p < 0.05 compared to 5mM control; n=4; data expressed as mean ± SEM, 
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Figure 3.2  
WST-1 cell survival assay at different glucose concentrations. HRMECs exposed 
to increasing concentrations of D-glucose for 24 hours exhibited decreased cell 
viability as measured by a WST-1 assay. Compared to 5mM D-glucose, cell 
viability was significantly decreased at 25mM, 50mM and 100mM. [* p < 0.05 
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Figure 3.3  
Real time RT-PCR analysis of VEGF mRNA levels at different durations of 
glucose exposure. HRMECs exposed to 25mM (high glucose; HG) glucose for 24 
and 48 hours demonstrated significantly increased VEGF mRNA compared to 
5mM (normal glucose; NG).  These differences were not observed at time points 
earlier than 24 hours. [* p < 0.05 compared to NG; n=4; data expressed as mean 
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3.2 miR-200b and VEGF are altered in human retinal endothelial cells 
exposed to high levels of glucose 
 To verify the effects of glucose exposure on miR-200b expression, 
HRMECs were exposed to 25mM D-glucose for 24 and 48 hours. An equimolar 
L-glucose treatment (osmotic control; OSM) was also used. L-glucose is 
metabolically inactive and does not cause oxidative stress and hyperglycemia-
induced signaling changes as D-glucose does (91,92). At both 24 and 48 hours, 
miR-200b levels showed significant decrease in HG compared to NG and OSM 
controls (Figure 3.4A). In parallel, VEGF showed significantly increased levels in 
HG compared to NG and OSM controls (Figure 3.4B). This result is consistent 
with previous work performed in our laboratory in bovine retinal endothelial cells. 
This is the first time miR-200b decrease has been observed in human endothelial 
cells isolated from the retina. This finding further strengthens the relationship 
between hyperglycemia and decreased miR-200b expression in the context of 
diabetic retinopathy.  
 
3.3 PRC2 components are altered in endothelial cells exposed to high 
glucose levels  
 Once decreased miR-200b and increased VEGF was established in 
HRMECs exposed to HG, the mRNA levels of several genes associated with the 
PRC2 complex was measured by qPCR. These included EZH2, the 











Real time RT-PCR analysis of miR-200b (A) and VEGF (B) in HRMECs exposed 
to 5mM D-glucose (NG) 25mM D-glucose (HG) and 20mM L-glucose+5mM D-
glucose (osmotic control; OSM). HRMECs cultured for 24 hours and 48 hours in 
HG showed significantly decreased levels of miR-200b with parallel increased 
levels of VEGF expression compared to NG and OSM. [* p < 0.05 compared to 
NG; n=6; data expressed as mean ± SEM, normalized to β-actin and expressed 
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PRC2, and KDM6A and KDM6B, which are the demethylases associated with 
H3K27me3 and thus oppose PRC2 activity.  
At both 24 and 48 hours in HG, mRNA of EZH2, EED and SUZ12 were 
elevated compared to NG and OSM controls (Figure 3.5). These observations 
show increased expression of the PRC2 components, which were hypothesized 
to negatively regulate miR-200b expression. Thus, this finding supports the 
hypothesis by correlating the increased expression of the PRC2 components with 
the decrease in miR-200b.  
Furthermore, no difference was observed in expression levels of KDM6A 
and KDM6B between NG, HG and OSM controls (Figure 3.6). Interestingly, 
KDM6A was observed to significantly decrease in HG at the 48 hour time point 
(Figure 3.6A). This suggests there is no change or even a decrease in 
demethylase expression for H3K27 methylation. Altogether, an increase in 
expression of PRC2 with no change or decrease in demethylase expression 
suggests a shift towards increase of H3K27me3 in HG. Overall, these 
experiments provide correlational evidence linking PRC2 to negatively regulating 
miR-200b in HG, though additional supporting evidence is necessary.  
 
3.4 PRC2 activity is increased specifically at the miR-200b promoter region 
 To demonstrate the involvement of PRC2 at the level of the genome and 
chromatin modifications, ChIP was performed using antibodies for H3K27me3. 
Negative control antibody IgG was used to demonstrate specificity of the 











Real time RT-PCR analysis of PRC2 components in HRMECs exposed to 5mM 
D-glucose (NG), 25mM D-glucose (HG), and 20mM L-glucose+5mM D-glucose 
(OSM). After 24 and 48 hour exposure to D-glucose, levels of EZH2, EED and 
SUZ12, were significantly increased compared to NG and OSM controls. [* p < 
0.05 compared to NG; n=6; data expressed as mean ± SEM, normalized to β-
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Real time RT-PCR analysis of demethylases for H3K27me3 in HRMECs 
exposed to 5mM D-glucose (NG), 25mM D-glucose (HG), and 20mM L-
glucose+5mM D-glucose (OSM). After 24 exposure to D-glucose, KDM6A and 
KDM6B levels did not change in HG. After 48 hours, KDM6A was significantly 
decreased compared to NG and OSM controls, while KDM6B showed no 
change. [* p < 0.05 compared to NG; n=6; data expressed as mean ± SEM, 
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immunoprecipitated to measure transcriptional activity of miR-200b at the level of 
the genome in addition to the RT-PCR results demonstrated above. Ascitic was 
used as a negative control for this antibody as provided by the manufacturer.  
Following immunoprecipitation and qPCR analysis, H3K27me3 was found 
to be significantly increased at the miR-200b promoter region in HG compared to 
NG controls (Figure 3.7). IgG isotype control pull down showed significantly less 
association than the H3K27me3-specific antibody. Also, Pol2 was found to be 
significantly decreased at the miR-200b promoter region in HG compared to NG 
controls (Figure 3.8). Again, specificity of this antibody was demonstrated as 
association with the negative control was minimal. Therefore, this increase of the 
H3K27me3, which is specific to the PRC2 complex, demonstrates a strong 
regulatory relationship between PRC2 and miR-200b at the level of chromatin 
modification. Furthermore, since this type of methylation is believed to be 
repressing and is associated with closed chromatin, the observation of 
decreased Pol2 association at the miR-200b promoter region further supports the 
mechanism and accounts for the decrease in miR-200b expression 
demonstrated earlier in this project. Altogether, these results paint a picture of 
the genomic events occurring at the miR-200b promoter region in HG, and 
further support that PRC2 may regulate miR-200b in diabetes. 
 Finally, to improve the specificity of this mechanism, areas of the genome 
with well-known association to the targets that were immunoprecipitated were 
measured by qPCR. No significant differences were observed in H3K27me3 and 










ChIP-qPCR analysis of H3K27 trimethylation (H3K27me3) at the miR-200b 
promoter region. Association of H3K27me3 at the miR-200b promoter region was 
significantly increased in 25mM (HG) glucose compared to 5mM (NG) glucose. 
Association of IgG negative control antibody was minimal and showed no 
difference between NG and HG. [* p < 0.05 compared to NG; n=3; data 
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ChIP-qPCR analysis of RNA polymerase 2 (Pol2) at the miR-200b promoter 
region. Association of Pol2 at the miR-200b promoter region was significantly 
decreased in 25mM (HG) glucose compared to 5mM (NG) glucose. Association 
of ascitic fluid (negative control) was minimal and showed no difference between 
NG and HG. [* p < 0.05 compared to NG; n=3; data expressed as mean 
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NG and HG, though specificity between the specific and non-specific antibodies 
was still observed (Figures 3.9 and 3.10). These negative control experiments 
further support that PRC2 specifically regulates miR-200b in HG, as these 
changes in H3K27me3 and Pol2 association are specific to certain genomic 
regions and are not global. 
 
3.5 Loss of function analysis using DZNep inhibitor demonstrates a cause-
and-effect relationship between PRC2 and miR-200b expression 
To demonstrate a cause-and-effect relationship between PRC2 and miR-
200b, a chemical inhibitor for H3K27me3, DZNep, was used. Prior to 
experimenting with DZNep, the potential toxicity of different concentrations of 
DZNep was measured using a WST-1 cell viability assay. Compared to DMSO 
control, DZNep showed increased survival at all concentrations (Figure 3.11). 
Significantly increased toxicity was observed at 500µM DZNep and 5% DMSO. 
The concentration of 5µM was selected for further studies. 
HRMECs treated for 24 hours with DZNep showed significantly higher 
miR-200b levels in both NG and HG compared to the other controls (Figure 
3.12A). In parallel, VEGF mRNA was significantly decreased when HRMECs 
were treated with DZNep compared to all other controls (Figure 3.12B). Since 
PRC2 was hypothesized to negatively inhibit miR-200b, through its repressing 
methylation-mark, increased expression of miR-200b would be expected by 










ChIP-qPCR analysis of H3K27 trimethylation (H3K27me3) at the human alpha-
satelite region. Association of Pol2 at the human alpha satellite region showed no 
significant change between 25mM (HG) glucose and 5mM (NG) glucose. 
Association of IgG negative control antibody was minimal and showed no 
difference between NG and HG. [* p < 0.05 compared to NG; n=3; data 






















































Figure 3.10  
ChIP-qPCR analysis of RNA polymerase 2 (Pol2) at the GAPDH promoter 
region. Association of Pol2 at the GAPDH promoter region showed no significant 
difference between 25mM (HG) glucose and 5mM (NG) glucose. Association of 
ascitic fluid (negative control) was minimal and showed no difference between 
NG and HG. [* p < 0.05 compared to NG; n=3; data expressed as mean 
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Figure 3.11  
WST-1 cell viability assay shows that HRMECs exposed to 3-Deazaneplanocin A 
(DZNep) for 24 hours increased in viability compared to an equivalent 
concentration of DMSO. [* p < 0.05 compared to DMSO control; n=4; data 
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Real time RT-PCR analysis of miR-200b and VEGF levels in HRMECs treated 
with 3-Deazaneplanocin A (DZNep) in 25mM (HG) glucose or 5mM (NG) 
glucose). After 24 exposure to DZNep in NG and HG, miR-200b levels were 
significantly increased with parallel decreased levels of VEGF compared to 
controls. [NG = 5mM D-glucose, HG = 25mM D-glucose, NG+DMSO = 5mM D-
glucose + 0.05% DMSO, HG+DMSO= 25mM D-glucose + 0.05% DMSO, 
NG+DZNEP = 5mM D-glucose + 5µM DZNep, HG+DZNEP = 25mM + 5µM 
DZNep; identical letters represent groups that are not significantly different; p < 
0.05; n=6; data expressed as mean ± SEM, normalized to β-actin for VEGF and 
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VEGF mRNA, a target of miR-200b, providing evidence to support the hypothesis 
by showing a cause-and-effect relationship by using loss-of-inhibition. 
 
3.6 Loss of function with siRNA demonstrates that SUZ12 is of importance 
in PRC2-mediated regulation of miR-200b 
 To further eludicate the role of specific components of PRC2 in the 
regulation of miR-200b, siRNA-mediated gene knockdown of EZH2 and SUZ12 
was performed. Control siRNA was used as a negative control. Knockdown 
efficiency was verified by RT-PCR and efficacy was verified by measuring the 
transcript levels of a known target of PRC2 (Figures 3.13 and 3.14). In HG, 
HRMECs transfected with control siRNA showed a significant decrease in miR-
200b expression and increase in VEGF expression (Figure 3.15). When EZH2 
was silenced in HG, miR-200b and VEGF showed no differences in expression 
compared to HRMECs treated with control siRNA in HG (Figure 3.15). However, 
silencing of SUZ12 increased miR-200b and decreased VEGF, with levels similar 
to HRMECs transfected with control siRNA in NG (Figure 3.15). In addition, a 
tube formation assay was conducted to provide a functional correlate. HRMECs 
transfected with control siRNA and EZH2 siRNA in HG showed significantly 
increased branching compared to HRMECs transfected with control siRNA in NG 
(Figure 3.16). HRMECs treated with SUZ12 siRNA in HG showed decreased 
branching, equivalent to HRMECs treated with control siRNA in NG (Figure 
3.16). Altogether, this data suggests that SUZ12 is important in regulating miR-








Figure 3.13  
Real time RT-PCR analysis of EZH2 and SUZ12 in HRMECs transfected with 
control or specific siRNA. When cultured in 25mM (HG) glucose, HRMECs 
transfected with EZH2 siRNA showed significantly decreased levels of EZH2 
compared to HRMECs transfected with control siRNA. Furthermore, HRMECs 
transfected with SUZ12 siRNA showed significantly decreased levels of SUZ12 
compared to HRMECs transfected with control siRNA. [* p < 0.05 compared to 
HG+control siRNA; n=6; data expressed as mean ± SEM, normalized to β-actin 




























































































Real time RT-PCR analysis of VASH1 in HRMECs exposed to 25mM (HG) 
glucose with EZH2 or SUZ12 siRNA. VASH1 mRNA levels were significantly 
increased in HRMECs transfected with EZH2 and SUZ12 siRNA compared to 
HRMECs transfected with control siRNA. [* p < 0.05 compared to HG+control 
siRNA; n=6; data expressed as mean ± SEM, normalized to β-actin and 
























































Real time RT-PCR analysis of miR-200b and VEGF levels in HRMECs 
transfected with EZH2 or SUZ12 siRNAs after 48 hour exposure to 25mM (HG) 
glucose or 5mM (NG) glucose). In HRMECs transfected with EZH2 siRNA in HG, 
miR-200b and VEGF expression was not significantly different from HG+control 
siRNA but decreased compared to NG+control siRNA. In HRMECs transfected 
with SUZ12 siRNA in HG, miR-200b was significantly increased with parallel 
decreased levels of VEGF compared to HRMECs transfected with control siRNA, 
with levels similar to NG+control siRNA. [NG+control siRNA = 5mM D-glucose + 
100nM control siRNA, HG+control siRNA = 25mM D-glucose + 100nM control 
siRNA, HG+EZH2 siRNA = 25mM D-glucose + 100nM EZH2 siRNA, HG+SUZ12 
siRNA = 25mM + 100nM SUZ12 siRNA; identical letters represent groups that 
are not significantly different; p < 0.05; n=6; data expressed as mean ± SEM, 
































































































Tube formation assay as a measure endothelial branching in HRMECs 
transfected with various siRNA. 1.5×104 were seeded on top of Matrigel and 
incubated for 16 hours at 37°C to assess tubule formation. HRMECs transfected 
with HG+control siRNA demonstrated significantly increased branching 
compared to NG+control siRNA. Transfection of EZH2 siRNA did not reduce 
endothelial branching significantly compared to HG+control siRNA. However, 
transfection of SUZ12 siRNA significantly reduced endothelial branching 
compared to HG+control siRNA. [NG+control siRNA = transfected with 100nM 
control siRNA and incubated for 16h in 5mM D-glucose following seeding, 
HG+control siRNA = transfected with 100nM control siRNA and incubated for 
16h in 25mM D-glucose following seeding, HG+EZH2 siRNA = transfected with 
100nM EZH2 siRNA and incubated for 16h in 25mM D-glucose following 
seeding, HG+SUZ12 siRNA = transfected with 100nM SUZ12 siRNA and 
incubated for 16h in 25mM D-glucose following seeding; identical letters 
represent groups that are not significantly different; p < 0.05; n=3 biological 
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3.7 PRC2 involvement in other endothelial cell types and in target tissues 
of diabetic complications 
Finally, the expression of PRC2 components was measured in retinal 
tissues of animal models of diabetes. We used streptozotocin-induced (STZ) rat 
and mouse models. All clinical data on these models is previous published 
(93,94). We used RNA isolated from retinal tissues of these models to determine 
whether changes seen in retinal endothelial cells are also present in vivo. EZH2, 
EED and SUZ12 were significantly increased in the retinal tissue of diabetic 
animals compared to non-diabetic controls (Figure 3.17). This finding is 
consistent with the in vitro data produced in this project and suggests that PRC2-
mediated regulation of miR-200b may be relevant in vivo.  
Furthermore, the expression of PRC2 components was measured in 
human dermal microvascular endothelial cells isolated from healthy individuals 
(HDMECs), from a patient with type 1 diabetes (Type 1) and a patient with type 2 
diabetes, all treated in NG or HG. Significantly increased expression of PRC2 
was observed in all cell types treated in HG (Figure 3.18). This suggests that 
PRC2 may be relevant in endothelial cells and may not be specific to retinal 
endothelial cells. This opens up the exciting possibility of common pathogenic 









Real time RT-PCR analysis of PRC2 component expression in animal retinal 
tissue from streptozotocin (STZ) induced diabetic and control animals. After 1 
month of diabetes, EZH2, EED and SUZ12 levels were increased in rat retinal 
tissue from diabetic animals compared to control animals. After 2 months of 
diabetes, EZH2, EED and SUZ12 levels were increased in mouse retinal tissue 
of diabetic animals compared to controls. [* p < 0.05 compared to control; n=6; 
data expressed as mean ± SEM, normalized to β-actin and expressed as a fold 
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Figure 3.18  
Real time RT-PCR analysis of PRC2 components in human dermal 
microvascular endothelial cells (HDMECs) of various origins. In non-diabetic 
adult HDMECs, EED and SUZ12 levels were significantly increased by HG. In 
HDMECs isolated from patients with diabetes (Type 1 & Type 2), EZH2, EED 
and SUZ12 were significantly increased in HG compared to NG controls. 
[HDMECs = human dermal microvascular endothelial cells, Type 1 = HDMECs 
isolated from a patient with type 1 diabetes, Type 2 = HDMECs isolated from a 
patient with type 2 diabetes; * p < 0.05 compared to NG; n=6; data expressed as 
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Our key findings are: 1) miR-200b and VEGF are altered in HRMECs 
exposed to glucose, 2) PRC2 component mRNA and activity at the miR-200b 
promoter region is in HRMECs exposed to glucose, 3) treatment with DZNep 
inhibitor and transfection of SUZ12 siRNA increased miR-200b and decreased 
VEGF levels, and 4) PRC2 components are altered in retinal tissues from 
diabetic animals and other endothelial cell types exposed to high glucose. 
Histone methylation as a mechanism for a dynamic response to external stimuli, 
like hyperglycemia, is a new way of thinking. Few mediators and types of 
methylation have been studied in the context of diabetic complications thus far. 
H3K27 methylation research has been expanding in the cancer field but remains 
uninvestigated in diabetes. Furthermore, recent evidence from cancer research 
suggests that the major methyltransferase complex for H3K27 trimethylation, 
PRC2, is involved in silencing several miRNA involved in cancer, including miR-
200b. Since miR-200b is also involved in diabetic retinopathy, a similar 
underlying mechanism may be present and is worth investigating.  
HRMECs exposed to high glucose levels typically seen in diabetes 
showed decreased miR-200b with parallel increased VEGF. As mentioned 
earlier, there has been some controversy over the directionality of whether miR-
200b becomes repressed or overexpressed in diabetic retinopathy. Different 
investigations have found conflicting results, although differences in animal 
model choice and cell culture conditions may account for this (95). Never the 
less, replicating miR-200b repression in high glucose conditions was an 
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important starting point in this study and verified results produced previously in 
our laboratory. Furthermore, this investigation showed repressed miR-200b in a 
relatively new cell type, which was isolated from human retina. This further 
strengthens the relevance of this in vitro model to the in vivo disease, as organ-
specific signaling is sometimes apparent in diabetes (ie. not all organs respond in 
the same manner to hyperglycemia). Therefore, this cell type was chosen for all 
subsequent experiments for its relevance to the organ of interest. 
Establishment of correlational evidence between miR-200b repression and 
PRC2 was important to first investigating a potential regulatory relationship. 
Though many proteins and lncRNA are involved in the PRC2 complex, three 
major components were selected for investigation. EZH2 is the major 
methyltransferase component while EED and SUZ12 are the major adaptor 
proteins. Expression of the major PRC2 components was increased in HG. 
Furthermore, this increase was specific to D-glucose treatment but not L-glucose. 
This suggests that PRC2 expression is increased due to signaling induced by 
hyperglycemia, and not simply due to osmolarity changes. This could be due to 
induction of certain transcription factors. For example, hypoxia inducible factor 1 
alpha (HIF-1α) has been shown to become stabilized and increase in 
transcriptional activity by high glucose in brain endothelial cells (96). 
Furthermore, HIF-1α has been shown to regulate EZH2 and may be responsible 
for regulating others genes in the PRC2 complex (97,98). Further investigation 
into HIF-1alpha stabilization would be suggest as a possible upstream 
mechanism of PRC2 induction in hyperglycemia.  
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Interestingly, after 24 hours of glucose exposure, no change was 
observed in the demethylases for H3K27me3, KDM6A and KDM6B. 
Furthermore, after 48 hours of glucose treatment, KDM6A was decreased 
relative to NG controls, while KDM6B again showed no change. Although 
increased mRNA expression of PRC2 components, and no change or decrease 
in KDM6A/B mRNA, does not imply a direct increase in their activity, it does 
suggest that PRC2 activity may be increased through increased expression. 
Further investigating these components at the protein level would strengthen this 
relationship between high glucose and increased PRC2 expression.  
Most importantly, H3K27me3 was increased in HG specifically at the miR-
200b promoter region, just upstream of the transcriptional start site. This increase 
in H3K27 methylation, a repressing type of methylation, suggests formation of 
closed, inaccessible chromatin and accounts for the decreased expression of 
miR-200b. Since PRC2 mediates this type of methylation, this observation further 
strengthens the hypothesis that PRC2 regulates miR-200b in response to 
hyperglycemia. Furthermore, RNA Pol2 association at the same promoter region 
was decreased in HG, further suggesting that heterochromatin was formed and 
that decreased expression of miR-200b in HG is regulated at the genome level. 
Finally, these changes in qPCR appear to be specific to the miR-200b promoter 
region. At the human alpha-satelite region, an area of heterochromain well 
known to associate with H3K27me3, no changes were observed in H3K27me3. 
Also, at the GAPDH promoter region, a highly expressed area of the genome, no 
changes were observed in Pol2 association. Therefore, H3K27me3 is increased 
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specifically, while Pol2 association is decreased specifically, at the miR-200b 
promoter region. This is one of the first investigations to connect two epigenetic 
mechanism, ie. histone methylation and microRNAs, in the context of a 
complication of diabetes. While there is no doubt that PRC2 regulates other 
genes, miR-200b is one gene that becomes repressed in response to PRC2 
induction in HG.  
ChIP-qPCR is a powerful technique for elucidating changes in chromatin 
modifications and transcriptional machinery recruitment. However, ChIP-qPCR is 
limited in the range of which changes can be determined because primers must 
be designed to specific regions. By combining ChIP with DNA sequencing (ChIP-
seq), a greater overall picture of the genomic landscape can be mapped, 
providing information on how the overall miR-200 gene is affected, as well as if 
H3K27me3 affects other genes.  
Cause-and-effect experimentation was important to further demonstrating 
a regulatory relationship between PRC2 and miR-200b. Using a chemical 
inhibitor of PRC2 and H3K27me3, DZNEP, miR-200b expression was 
significantly increased while VEGF was decreased in parallel. DZNep is not 
specific for H3K27me3 inhibition, thus siRNA-mediated gene knockdown was 
used to further elucidate the mechanism (90). siRNA against EZH2 and SUZ12 
were used because these targets have been directly linked to regulating miR-
200b in neoplasia. Interestingly, silencing of EZH2 in HG showed no significant 
changes in miR-200b and VEGF levels when compared to control siRNA. 
However, in HG, silencing of SUZ12 produced significantly increased miR-200b 
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and decreased VEGF expression compared to control siRNA, and similar 
expression to control siRNA in NG. Furthermore, silencing of SUZ12 produced 
decreased endothelial branching compared to control siRNA and EZH2 siRNA, 
indicating functional alterations in endothelial cells and possibly a proxy of VEGF 
action. Therefore, it is possible that PRC2 regulation is dependent on SUZ12 and 
not EZH2. This is interesting because EZH2 is the major methyltransferase 
component for PRC2 and has been demonstrated to regulate miR-200b in 
neoplasia. EZH2 is often regarded as the most important component for PRC2 
regulation, however in our study SUZ12 was shown to be important for miR-200b 
regulation.  One possibility is that silencing of EZH2 in HG is insufficient to 
restore miR-200b levels to normal levels because SUZ12 is still able to occupy 
the miR-200b promoter region. Studies have shown that recruitment of PRC2 is 
dependent on SUZ12 (82,83,99). Furthermore, EZH1, a homolog of EZH2, also 
catalyzes for H3K27me3 and has been shown to compensate for EZH2-
knockdown by replacing it in PRC2 complex (100,101). Thus, silencing of SUZ12 
prevents methylation at the miR-200b promoter region by preventing overall 
recruitment of PRC2, while silencing of EZH2 may be compensated by EZH1. 
Although EZH1 was not examined in this investigation, it may explain why SUZ12 
appears to be important in PRC2-mediated regulation of miR-200b. Additional 
experimentation is necessary to elucidate the interplay of these specific 
components of PRC2. 
Finally, additional correlational evidence using other models, including 
animal models and other endothelial cell types, suggests the potential 
	  92 
importance of PRC2 in diabetic retinopathy. In retinal tissue from diabetic rats 
and mice EZH2, EED and SUZ12 expression was increased relative to non-
diabetic control animals. Therefore, this mechanism may be relevant in vivo and 
requires further investigation to determine the therapeutic potential of inhibiting 
these targets to prevent the microvascular changes associated with diabetes. 
Furthermore, PRC2 components were elevated in HDMECs exposed to HG 
isolated from healthy individuals, as well as individuals with type 1 and type 2 
diabetes. This further strengthens the mechanism that PRC2 components are 
elevated in HG in endothelial cells. Furthermore, the increase in HG observed in 
endothelial cells isolated from diabetic patients offers some interesting 
conclusions. These cells were isolated from patients who had diabetes for 
several years (ie. greater than 20 years). However, when treated in HG, PRC2 
components were still overexpressed suggesting that hyperglycemia-induced 
upregulation does not become dampened. Thus, PRC2 and miR-200b may be 
important in other complications of diabetes.  
Many different experiments were performed to elucidate this regulatory 
mechanism. One major limitation is that most of this work was done at the 
RNA/transcript level. Since this project was focused on determining expression 
changes at the level of the genome, RT-PCR was chosen as the major technique 
used to show changes. While expression at the RNA and protein levels are often 
parallel, replication of the changes at the protein level, such as by using Western 
Blotting or ELISA, would further strengthen the results. Furthermore, the 
knockdown efficiency between EZH2 and SUZ12 siRNA transfections differed 
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slightly, which may also explain why EZH2 silencing was ineffective in elevating 
miR-200b levels while SUZ12 silencing was effective. Finally, tube formation 
assay was used as a proxy of VEGF activity. Direct testing using ELISA or other 
techniques, such as a permeability assay, would further strengthen these results.  
None-the-less, the battery of experiments performed suggests increased PRC2 
expression and activity at the miR-200b promoter region, providing rationale for 
why miR-200b becomes repressed in diabetes. 
While other work in the field of epigenetics in diabetic complications has 
focused on either histone methylation or miRNAs, this project has shown how 
these epigenetic mechanisms work together to regulate VEGF. This project has 
demonstrated that PRC2 negatively regulates miR-200b and thus appears to be 
a good therapeutic target in diabetic retinopathy. Due to its nature as a 
multimeric enzyme complex, it can potentially be targeted with a small molecule. 
While much work is needed to design a chemical inhibitor that would selectively 
target this complex and be effective in being transported to the retina, an organ 
with its own selective permeability, this work has demonstrated another 
therapeutic strategy, which may show efficacy in the prevention of diabetic 
retinopathy. It is hoped that continued investigation into this complex will lead to 
a small molecule therapy for diabetic retinopathy that can be more accessible 
and cost effective in treating diabetic retinopathy, though such goals are far in the 
distance.  
In summary, we show that PRC2 regulates miR-200b in retinal endothelial 
cells through H3K27me3 repression (Figure 4.1). This is one of the first 
	  94 
investigations to connect histone methylation and miRNA regulation in the 
context of diabetic retinopathy. Ultimately, this work builds on the 
characterization of miRNA our lab has studied by elucidating a new regulation 
mechanism. Investigating such mechanisms is important to further our 
understanding of the signaling events that occur in response to hyperglycemia in 
diabetic retinopathy, as well as developing novel treatment strategies to maintain 
the quality of life of patients with diabetes. 	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Figure 4.1  
Summary diagram of key findings. Findings of this study demonstrate a 
regulatory relationship between PRC2 and miR-200b, of which SUZ12 appears 
to be the most important component in mediating this regulation (indicated by *). 
PRC2 is increased by high glucose, leading to repression of miR-200b and 
subsequently causing a loss-of-inhibition on VEGF levels. Altered VEGF 
production can lead to increased vascular permeability and neovascularization in 
diabetic retinopathy, demonstrating potential importance of PRC2 as a 


























To further determine the efficacy of PRC2 inhibition in the prevention of 
microvascular changes in diabetic retinopathy, an in vivo model of diabetes 


















appears to be the most effective in the study of this complex in diabetic 
retinopathy, based on the in vitro results. Furthermore, while the linear regulation 
of PRC2, miR-200b and VEGF was focused on in this project, PRC2 and miR-
200b have been demonstrated in other studies to regulate genes of relevance in 
diabetic retinopathy. For example, PRC2 has been demonstrated to regulate 
VASH1, an anti-angiogenic factor. Inhibition of PRC2 may lead to increased 
VASH1, which may be desirable to prevent permeability changes and 
neovascularization associated with diabetic retinopathy (79,85). Also, miR-200b 
has been shown to regulate p300, a histone acetyltransferase associated with 
activation of matrix protein expression in diabetic retinopathy (53). Thus, while 
PRC2 was demonstrated to regulate miR-200b directly and VEGF indirectly in 
diabetic retinopathy, many potential interactions may be relevant. This highlights 
the importance of this complex in diabetic retinopathy as a therapeutic target. 
Additional experimentation in this area could further strengthen the potential 
therapeutic efficacy of PRC2 inhibition in diabetic retinopathy.  
Finally PRC2 has numerous interactions with lncRNA, which opens up the 
possibility for future research into an extremely novel field. LncRNA (ie. HOTAIR) 
act as molecular scaffolds and may mediate other interactions with histone 
remodeling complexes (102). Furthermore, lncRNA (ie. ANRIL) act as 
recruitment flags for PRC2 to mediate specific association to genome regions 
(83). Investigations into these lncRNA in parallel with PRC2 may reveal a more 
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